Trends in diabetes medication use in Canada, England, Scotland and Australia: a repeated cross-sectional analysis (2012-2017)

Michelle Greiver*, Alys Havard, Juliana Kuster Filipe Bowles, Sumeet Kalia, Tao Chen, Babak Aliarzadeh, Rahim Moineddin, Julian Sherlock, William Hinton, Francis Sullivan, Braden O'Neill, Conrad Pow, Aashka Bhatt, Fahrurrozi Rahman, Bernardo Meza-Torres, Melisa Litchfield, Simon de Lusignan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)
8 Downloads (Pure)

Abstract

Background
Several new classes of glucose lowering medications have been introduced in the past two decades. Some, such as Sodium-glucose cotransporter 2 inhibitors (SGLT2s), have evidence of improved cardiovascular outcomes, while others, such as Dipeptidyl peptidase-4 inhibitors (DPP4s), do not. It is therefore important to identify their uptake, in order to find ways to support the use of more effective medications.


Aims
We studied the uptake of these new classes amongst patients with type 2 diabetes.


Design and setting Retrospective repeated cross-sectional analysis. We compared rates of medication uptake in Australia, Canada, England and Scotland.


Method
We used primary care Electronic Medical Data on prescriptions (Canada, UK) and dispensing data (Australia) from 2012 to 2017. We included persons aged 40 years or over on at least one glucose-lowering drug class in each year of interest, excluding those on insulin only. We determined proportions of patients in each nation, for each year, on each class of medication, and on combinations of classes.


Results
By 2017, data from 238,609 patients were included. The proportion of patients on sulfonylureas (SUs) decreased in three out of four nations, while metformin decreased in Canada. Use of combinations of metformin and new drug classes increased in all nations, replacing combinations involving SUs. In 2017 more patients were on DPP4s (between 19.1% and 27.6%) than on SGLT2s (between 10.1% and 15.3%).


Conclusions
New drugs are displacing SUs. However, despite evidence of better outcomes, the adoption of SGLT2s lagged behind DPP4s.
Original languageEnglish
Pages (from-to)e209-e218
Number of pages10
JournalBritish Journal of General Practice
Volume71
Issue number704
Early online date25 Feb 2021
DOIs
Publication statusPublished - 1 Mar 2021

Keywords

  • Primary healthcare
  • Diabetes mellitus, Type 2
  • Drug Therapy
  • Pharmacoepidemiology
  • Electronic health records

Fingerprint

Dive into the research topics of 'Trends in diabetes medication use in Canada, England, Scotland and Australia: a repeated cross-sectional analysis (2012-2017)'. Together they form a unique fingerprint.

Cite this